{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:37:44Z","timestamp":1775137064283,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["406192\/2023-5"],"award-info":[{"award-number":["406192\/2023-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["140875\/2024-7"],"award-info":[{"award-number":["140875\/2024-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018799","name":"Instituto Nacional de Pesquisas em Resist\u00eancia a Antimicrobianos","doi-asserted-by":"publisher","award":["INCT \u2013 MCTI\/CNPq\/CAPES\/FAPs n\u00ba 16\/2014"],"award-info":[{"award-number":["INCT \u2013 MCTI\/CNPq\/CAPES\/FAPs n\u00ba 16\/2014"]}],"id":[{"id":"10.13039\/100018799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018799","name":"Instituto Nacional de Pesquisas em Resist\u00eancia a Antimicrobianos","doi-asserted-by":"publisher","award":["INCT \u2013 MCTI\/CNPq\/CAPES\/FAPs n\u00ba 16\/2014"],"award-info":[{"award-number":["INCT \u2013 MCTI\/CNPq\/CAPES\/FAPs n\u00ba 16\/2014"]}],"id":[{"id":"10.13039\/100018799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.670254\/2022-0"],"award-info":[{"award-number":["88887.670254\/2022-0"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["8887.716776\/2022-00"],"award-info":[{"award-number":["8887.716776\/2022-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00284-024-03897-1","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T16:01:19Z","timestamp":1727020879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Vitro Synergistic Activity of Rifampicin Combined with Minimal Effective Antibiotic Concentration (MEAC) of Polymyxin B Against Extensively Drug-Resistant, Carbapenem-, and Polymyxin B-Resistant Klebsiella pneumoniae Clinical Isolates"],"prefix":"10.1007","volume":"81","author":[{"given":"Nath\u00e1lia","family":"Abichabki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto Gambero","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00edsa Vieira","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Helena C\u00e2ndido","family":"Pocente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denissani Aparecida Ferrari Santos","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nat\u00e1lia Augusta Barbosa","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Thomaz Pereira","family":"Brancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nat\u00e1lia Columbaro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto \u00dabida Leite","family":"Braga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Bellissimo-Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valdes Roberto","family":"Bollela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana L\u00facia Costa","family":"Darini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-5739","authenticated-orcid":false,"given":"Leonardo Neves","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"3897_CR1","doi-asserted-by":"publisher","first-page":"a027011","DOI":"10.1101\/cshperspect.a027011","volume":"6","author":"DM Rothstein","year":"2016","unstructured":"Rothstein DM (2016) Rifamycins, alone and in combination. Cold Spring Harb Perspect Med 6:a027011. https:\/\/doi.org\/10.1101\/cshperspect.a027011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3897_CR2","volume-title":"The WHO AWaRe (access watch reserve) antibiotic book","author":"World Health Organization","year":"2023","unstructured":"World Health Organization (2023) The WHO AWaRe (access watch reserve) antibiotic book. WHO, Geneva"},{"key":"3897_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel L, Jayol A, Nordmann P (2017) Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30:557\u2013596. https:\/\/doi.org\/10.1128\/CMR.00064-16","journal-title":"Clin Microbiol Rev"},{"key":"3897_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","volume":"48","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis S, Kritsotakis EI, Gikas A (2020) Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection 48:835\u2013851","journal-title":"Infection"},{"key":"3897_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.14649","volume":"1496","author":"M Zhu","year":"2021","unstructured":"Zhu M, Tse MW, Weller J et al (2021) The future of antibiotics begins with discovering new combinations. Ann N Y Acad Sci 1496:82\u201396","journal-title":"Ann N Y Acad Sci"},{"key":"3897_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mib.2020.05.012","volume":"57","author":"GJ Sullivan","year":"2020","unstructured":"Sullivan GJ, Delgado NN, Maharjan R, Cain AK (2020) How antibiotics work together: molecular mechanisms behind combination therapy. Curr Opin Microbiol 57:31\u201340. https:\/\/doi.org\/10.1016\/j.mib.2020.05.012","journal-title":"Curr Opin Microbiol"},{"key":"3897_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02270-14","author":"F Baquero","year":"2014","unstructured":"Baquero F, Coque TM (2014) Widening the spaces of selection: evolution along sublethal antimicrobial gradients. mBio 5. https:\/\/doi.org\/10.1128\/mbio.02270-14","journal-title":"mBio 5"},{"key":"3897_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00050-19","author":"F Baquero","year":"2021","unstructured":"Baquero F, Mart\u00ednez JL, Lanza VF et al (2021) Evolutionary pathways and trajectories in antibiotic resistance. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00050-19","journal-title":"Clin Microbiol Rev"},{"key":"3897_CR9","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1128\/JCM.00088-14","volume":"52","author":"LN Andrade","year":"2014","unstructured":"Andrade LN, Vitali L, Gaspar GG et al (2014) Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone. J Clin Microbiol 52:2530\u20132535. https:\/\/doi.org\/10.1128\/JCM.00088-14","journal-title":"J Clin Microbiol"},{"key":"3897_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01669","author":"JK Palmeiro","year":"2019","unstructured":"Palmeiro JK, de Souza RF, Sch\u00f6rner MA et al (2019) Molecular epidemiology of multidrug-resistant Klebsiella pneumoniae isolates in a Brazilian tertiary hospital. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2019.01669","journal-title":"Front Microbiol"},{"key":"3897_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/antibiotics11060814","volume":"11","author":"GG Gaspar","year":"2022","unstructured":"Gaspar GG, Tamasco G, Abichabki N et al (2022) Nosocomial outbreak of extensively drug-resistant (polymyxin B and carbapenem) Klebsiella pneumoniae in a collapsed university hospital due to COVID-19 pandemic. Antibiotics 11:814. https:\/\/doi.org\/10.3390\/antibiotics11060814","journal-title":"Antibiotics"},{"key":"3897_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"key":"3897_CR13","unstructured":"EUCAST (2023) Antimicrobial susceptibility testing. https:\/\/www.eucast.org\/ast_of_bacteria\/. Accessed 9 Oct 2023"},{"key":"3897_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/jac\/dkx113","volume":"72","author":"S Foerster","year":"2017","unstructured":"Foerster S, Desilvestro V, Hathaway LJ et al (2017) A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Antimicrob Chemother 72:1961\u20131968. https:\/\/doi.org\/10.1093\/jac\/dkx113","journal-title":"J Antimicrob Chemother"},{"key":"3897_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1\u20131. https:\/\/doi.org\/10.1093\/jac\/dkg301","journal-title":"J Antimicrob Chemother"},{"key":"3897_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10393-8","author":"N Abichabki","year":"2022","unstructured":"Abichabki N, Zacharias LV, Moreira NC et al (2022) Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-10393-8","journal-title":"Sci Rep"},{"key":"3897_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00873-18","author":"T Brennan-Krohn","year":"2018","unstructured":"Brennan-Krohn T, Pironti A, Kirby JE (2018) Synergistic activity of colistin-containing combinations against colistin-resistant enterobacteriaceae. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00873-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s15010-021-01748-w","volume":"50","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Ioannou P, Kofteridis DD (2022) In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection 50:569\u2013581. https:\/\/doi.org\/10.1007\/s15010-021-01748-w","journal-title":"Infection"},{"key":"3897_CR19","unstructured":"BrCAST (2023) Tabelas de pontos de corte para interpreta\u00e7\u00e3o de CIMs e di\u00e2metros de halos - Brazilian Committee on Antimicrobial Susceptibility Testing - BrCAST"},{"key":"3897_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02875-z","author":"CR MacNair","year":"2018","unstructured":"MacNair CR, Stokes JM, Carfrae LA et al (2018) Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-02875-z","journal-title":"Nat Commun"},{"key":"3897_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jac\/dkm509","volume":"61","author":"M Bassetti","year":"2008","unstructured":"Bassetti M, Repetto E, Righi E et al (2008) Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61:417\u2013420. https:\/\/doi.org\/10.1093\/jac\/dkm509","journal-title":"J Antimicrob Chemother"},{"key":"3897_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","volume":"57","author":"E Durante-Mangoni","year":"2013","unstructured":"Durante-Mangoni E, Signoriello G, Andini R et al (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:349\u2013358. https:\/\/doi.org\/10.1093\/cid\/cit253","journal-title":"Clin Infect Dis"},{"key":"3897_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1017\/S095026881200194X","volume":"141","author":"H Aydemir","year":"2013","unstructured":"Aydemir H, Akduman D, Piskin N et al (2013) Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141:1214\u20131222. https:\/\/doi.org\/10.1017\/S095026881200194X","journal-title":"Epidemiol Infect"},{"key":"3897_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ijantimicag.2006.09.009","volume":"29","author":"A Pantopoulou","year":"2007","unstructured":"Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M et al (2007) Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29:51\u201355. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.09.009","journal-title":"Int J Antimicrob Agents"},{"key":"3897_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ijantimicag.2007.07.007","volume":"30","author":"M-F Tripodi","year":"2007","unstructured":"Tripodi M-F, Durante-Mangoni E, Fortunato R et al (2007) Comparative activities of colistin, rifampicin, imipenem and sulbactam\/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30:537\u2013540. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.07.007","journal-title":"Int J Antimicrob Agents"},{"key":"3897_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-109","author":"W Liang","year":"2011","unstructured":"Liang W, Liu XF, Huang J et al (2011) Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis. https:\/\/doi.org\/10.1186\/1471-2334-11-109","journal-title":"BMC Infect Dis"},{"key":"3897_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106902","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhu Y, Han ML et al (2023) Model-informed dose optimisation of polymyxin-rifampicin combination therapy against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106902","journal-title":"Int J Antimicrob Agents"},{"key":"3897_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diagmicrobio.2016.07.017","volume":"86","author":"DJ Hong","year":"2016","unstructured":"Hong DJ, Kim JO, Lee H et al (2016) In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis 86:184\u2013189. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.07.017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3897_CR29","doi-asserted-by":"publisher","first-page":"106344","DOI":"10.1016\/j.ijantimicag.2021.106344","volume":"57","author":"L Scudeller","year":"2021","unstructured":"Scudeller L, Righi E, Chiamenti M et al (2021) Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant gram-negative bacilli. Int J Antimicrob Agents 57:106344. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106344","journal-title":"Int J Antimicrob Agents"},{"key":"3897_CR30","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1128\/AAC.00703-13","volume":"57","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Bergen PJ, Bulitta JB et al (2013) Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother 57:3738\u20133745. https:\/\/doi.org\/10.1128\/AAC.00703-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR31","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/jac\/dkw213","volume":"71","author":"P Lagerb\u00e4ck","year":"2016","unstructured":"Lagerb\u00e4ck P, Khine WWT, Giske CG, T\u00e4ngd\u00e9n T (2016) Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments. J Antimicrob Chemother 71:2321\u20132325. https:\/\/doi.org\/10.1093\/jac\/dkw213","journal-title":"J Antimicrob Chemother"},{"key":"3897_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221106705","author":"L Sun","year":"2022","unstructured":"Sun L, Sun J, Ding S (2022) In vitro research of combination therapy for multidrug-resistant Klebsiella pneumoniae bloodstream infections. J Int Med Res. https:\/\/doi.org\/10.1177\/03000605221106705","journal-title":"J Int Med Res"},{"key":"3897_CR33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.cmi.2020.03.007","volume":"26","author":"P Wistrand-Yuen","year":"2020","unstructured":"Wistrand-Yuen P, Olsson A, Skarp K-P et al (2020) Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments. Clin Microbiol Infect 26:1214\u20131221. https:\/\/doi.org\/10.1016\/j.cmi.2020.03.007","journal-title":"Clin Microbiol Infect"},{"key":"3897_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02121-16","author":"JK Diep","year":"2017","unstructured":"Diep JK, Jacobs DM, Sharma R et al (2017) Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02121-16","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR35","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1128\/AAC.00179-13","volume":"57","author":"C Tascini","year":"2013","unstructured":"Tascini C, Tagliaferri E, Giani T et al (2013) Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 57:3990\u20133993. https:\/\/doi.org\/10.1128\/AAC.00179-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00912","author":"ME Pach\u00f3n-Ib\u00e1\u00f1ez","year":"2018","unstructured":"Pach\u00f3n-Ib\u00e1\u00f1ez ME, Labrador-Herrera G, Cebrero-Cangueiro T et al (2018) Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2018.00912","journal-title":"Front Microbiol"},{"key":"3897_CR37","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1128\/AAC.00741-13","volume":"58","author":"T T\u00e4ngd\u00e9n","year":"2014","unstructured":"T\u00e4ngd\u00e9n T, Hickman RA, Forsberg P et al (2014) Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-Producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58:1757\u20131762. https:\/\/doi.org\/10.1128\/AAC.00741-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00140-21","author":"S Wasserman","year":"2021","unstructured":"Wasserman S, Davis A, Stek C et al (2021) Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00140-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3897_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ipha.2024.01.004","author":"T Liu","year":"2024","unstructured":"Liu T, Zhou J, Liu X, Xu X (2024) Comparative study of colistin methanesulfonate and colistin sulfate\/polymyxin B in the treatment of ceftazidime-avibactam resistant gram-negative bacilli infections. Intell Pharm. https:\/\/doi.org\/10.1016\/j.ipha.2024.01.004","journal-title":"Intell Pharm"},{"key":"3897_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.01.012","author":"T Vieceli","year":"2024","unstructured":"Vieceli T, Henrique LR, Rech TH, Zavascki AP (2024) Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. J Infect Chemother. https:\/\/doi.org\/10.1016\/j.jiac.2024.01.012","journal-title":"J Infect Chemother"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03897-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-024-03897-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03897-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T17:06:44Z","timestamp":1729530404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-024-03897-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3897"],"URL":"https:\/\/doi.org\/10.1007\/s00284-024-03897-1","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,22]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo (CAAE: 48834921.9.0000.5403\u2014Protocol CEP\/FCFRP n\u00ba580).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"371"}}